Kornimate/medical-research-clean huggingface dataset:
the study of dachengqi decoction combined with probiotic l92 to improve the prognosis of patients with severe abdominal hypertension

Conditions: Dachengqi Decoction; Probiotic L92

Summary: patients with severe infections, wounds (burns), and severe pancreatitis often have abdominal hypertension (iah), which is an important objective manifestation of acute gastrointestinal failure in severe patients. timely diagnosis and effective intervention can improve the treatment rate of patients. in the early stage, we conducted clinical exploration and observational research on the treatment of iah with dachengqi decoction and lactobacillus in the treatment of critically ill patients including the above diseases, and achieved significant clinical effects. on this basis, it is planned to verify the protective effect of lactobacillus acidophilus l92, dachengqi decoction and the combination of the two on the gastrointestinal mucosal barrier function of patients with iah and the regulation of the intestinal flora, and analyze the intestinal mucosal barrier the relationship between intestinal flora and the prognosis of iah patients.


Eligibility criteria:
inclusion criteria: * inclusion and exclusion criteria and critically ill patients (acute severe pancreatitis, cervical spinal cord injury) who are 60 years old or older than 18 years old, expected to be mechanically ventilated in the icu, and hospitalized for more than 48 hours, replaced intra-abdominal pressure monitoring with bladder pressure measurement, and repeated on admission the results of the three measurements are ≥12 mmhg. exclusion criteria: * patients who have not signed the informed consent; cannot tolerate intra-abdominal pressure monitoring; pregnant women; patients after bladder surgery; systemic diseases and recent use of related drugs; previous infections, such as history of tuberculosis or ppd positive; previous high history of blood pressure, poor blood pressure control (sbp/dbp\>=140mmhg); patients with severe mental illness; long-term use of traditional chinese medicine, probiotics, gastric mucosal protectors, proton pump inhibitors, chemotherapy or immunosuppressive drugs, etc., such as admission the drug was not discontinued within the previous month.
a safety and efficacy study to evaluate rosacea

Conditions: Papulopustular Rosacea

Summary: to evaluate the safety, efficacy, and pharmacokinetic profile of ascending concentrations of the study medication compared with vehicle in subjects with rosacea.

this is primarily a safety study to evaluate the safety of aiv001 when administered to subjects with rosacea. exploratory efficacy measures will also be collected as well as pharmacokinetic profiles.

Eligibility criteria:
inclusion criteria: * healthy male and/or female subjects between the ages of 18 and 65 year with rosacea, 10 to 30 papules and pustules (at least 5 lesions within the treatment area on each facial side), and \< 2 nodules * presence of moderate to severe persistent erythema * total body weight \>45 kg exclusion criteria: * presence of any skin condition on the face that would interfere with the diagnosis or assessment of rosacea * extremely dark skin type that would confound the digital analysis of erythema (eg, fitzpatrick skin type 5 or 6) * excessive facial hair (eg, beards, sideburns, moustaches, etc.), birthmarks, or tattoos that would interfere with diagnosis or assessment of rosacea * use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day. * pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of non-hormonal contraception as outlined in this protocol from at least 14 days prior to start of treatment. * hypersensitivity or allergy to axitinib or any other component of the study treatment * use within 6 months prior to baseline and during the study of oral retinoids (eg, accutane®) or therapeutic vitamin a supplements of greater than 10,000 units/day (multivitamins are allowed). * use within 6 weeks prior to baseline and during the study of vasodilators or α-adrenergic receptor-blocking agents. * use within 1 month prior to baseline and during the study of 1) topical retinoids to the face, 2) systemic antibiotics know to have an impact on the severity of facial rosacea (eg, containing tetracycline and its derivatives, erythromycin and its derivatives, sulfamethoxazole, or trimethoprim), 3) systemic corticosteroids, or 4) facial light-based therapies

Keywords: rosacea
women's health initiative strong and healthy study

Conditions: Myocardial Infarction; Stroke; Cardiovascular Mortality; Hip Fractures; Falls; Mortality; Venous Thromboembolic Event; Peripheral Artery Disease; Physical Function; Coronary Revascularization; Mobility and Independence; Clinical (Non-hip) Fractures; Sleep; Depressive Symptoms

Summary: the whish trial applies state-of-the science behavioral principles and currently available technologies to deliver a physical activity intervention without face-to-face contact to \~25,000 older u.s. women expected to consent. it includes the national institute of aging (nia) go4life® exercise \& physical activity materials 3 and whish developed targeted materials based on go4life® to provide inspirational tips and recommendations about how to achieve nationally recommended levels of pa and overcome barriers to exercise, with a means for self-monitoring and setting personal goals. the intervention builds upon evidence-based behavioral science principles and intervention components that have proven to be effective in increasing pa in older women, with innovative adaptive approaches to tailoring the delivery to meet individual (personal) needs.


Eligibility criteria:
inclusion criteria: * currently enrolled in the women's health initiative (whi) extension study * known to be alive * cardiovascular outcomes will be available (enrolled in the whi medical records cohort or linked to medicare data) exclusion criteria: * inability to walk * dementia * residing in a nursing home

Keywords: physical activity national institute of aging go4life postmenopausal women balance strength exercise cardiovascular disease stroke mortality myocardial infarction falls venous thromboembolic event peripheral artery disease physical function mobility and independence coronary artery bypass graft (cabg) percutaneous coronary intervention (pci) hip fractures cardiovascular mortality clinical (non-hip) fractures sleep depressive symptoms
a clinical trial utilizing dantrolene in patients with ventricular arrhythmias.

Conditions: Ventricular Tachycardia

Summary: this is a randomized, placebo controlled trial of dantrolene (n= 84 participants) to demonstrate the feasibility of using i.v. dantrolene to study the effect of ryr2 inhibition on cardiac electrophysiology, hemodynamics and ventricular arrhythmia inducibility in patients with structural heart disease referred for vt ablation. the investigators will also explore the pharmacokinetic/pharmacodynamic relationship of i.v. dantrolene and it short-term effect on specific cardiac electrophysiologic and hemodynamic parameters.

the hypothesis to be tested is that ryr2 hyperactivity in patients with structural heart disease drives proarrhythmic changes in refractoriness and conduction, and decreases cardiac contractility, which promotes vt/vf. dantrolene, a currently available drug that inhibits ryr2, but has no na or k channel activity, will be used as a tool to study ryr2 modulation. the investigators propose a randomized controlled trial of dantrolene versus placebo in patients with structural heart disease referred for vt ablation to evaluate electrophysiologic, hemodynamic, and arrhythmia prevention endpoints. dantrolene's inhibition of ryr1 will also be studied to define its effect on muscle and respiratory strength in this clinical population, which will be important if dantrolene is to be considered for repurposing as an antiarrhythmic drug. the two aims are: aim 1: to conduct a randomized, placebo-controlled trial of dantrolene to study the effect of ryr inhibition on cardiac electrophysiology, hemodynamics, arrhythmia inducibility, muscle strength, and respiratory mechanics in patients with structural heart disease referred for vt ablation. aim 2: to explore the pharmacokinetic/pharmacodynamic relationship of i.v. dantrolene and its short-term effect on cardiac electrophysiology, hemodynamics, and muscle and respiratory strength.

Eligibility criteria:
inclusion criteria: * greater than or equal to 18 years of age * able to give written informed consent * referred for catheter-based vt ablation * structural heart disease (cardiomyopathy or rv/lv scar) * permanent pacemaker or implantable cardioverter defibrillator exclusion criteria: * mechanical ventricular support (e.g. lvad, ecmo) * nyha class iv heart failure * lvef \< 20% * morbid obesity (bmi \> 40 kg/m2) * severe renal insufficiency (gfr\<30 ml/min) * chronic liver disease (child pugh class a-c) * current use of calcium channel blockers * neuromuscular disorder (e.g. muscular dystrophy) * chronic obstructive pulmonary disease or restrictive lung disease requiring oxygen * therapy or history of intubation * pregnant or nursing * history of dysphagia

Keywords: ventricul tachycardia ablation
how body awareness promotes mental health during yoga and physical exercise

Conditions: Negative Thoughts; Mild Depression; Stress

Summary: the integrity of interoceptive networks is linked to resilience against depressive symptoms, whereas degradation of these networks is linked to apathy and deficits in emotion processing. the goal of this study is to compare two major styles of yoga and cardiovascular exercise through a 10-week training program to promote interoceptive awareness. the researchers hypothesize that improvement in affective symptomatology will be correlated with better interoceptive development. changes in mood related symptoms and interoception will be assessed at baseline, week 12 and week 14, in a cohort of adults aged 18-55.

a recent annual survey of u.s. college freshman has found consistently declining levels of emotional health over the past 25 years. exposure to such stress can have profound longitudinal effects on well being, influencing risk for disease later in life. physical exercise is linked to benefits across a variety of physical and psychological domains. while the affective and physiological consequences of exercise are well-documented, how they work to improve subjective well-being is unclear. it has been suggested that exercise promotes well-being by increasing interoception. the integrity of interoceptive networks is linked to resilience against depressive symptoms, whereas degradation of these networks is linked to apathy and deficits in emotion processing. the goal of this study is to compare two major styles of yoga and cardiovascular exercise through a 10-week training program to promote interoceptive awareness. the researchers hypothesize that improvement in affective symptomatology will be correlated with better interoceptive development. changes in mood related symptoms and interoception will be assessed at baseline, week 12 and week 14, in a cohort of adults aged 18-55.

Eligibility criteria:
inclusion criteria: * 18-55 years of age * have negative mood symptoms (depression, anxiety, stress) * is healthy and independent enough in daily life to attend study classes exclusion criteria: * pregnant women or women who are planning to become pregnant during the study period * history of structural brain disease, mass lesion, stroke, epilepsy * history of addictive disorder or significant substance abuse * neurological disorders or reversible causes of dementia * suicidality or history of psychosis * currently attending regular yoga or aerobic exercise practice, or participated in more than 6 formal meditation, aerobic, or yoga classes in the past 12 months * self-reported cognitive impairment and other disorders which may preclude safe participation in the program including acute major depression, bipolar or severe personality disorder
safety/efficacy study of subcutaneously injected prandial insulins compared to insulin lispro alone in participants with type 1 diabetes mellitus

Conditions: Diabetes Mellitus, Type 1

Summary: the purpose of the study is to compare humalog (insulin lispro)-recombinant human hyaluronidase (rhuph20) or novolog (insulin aspart)-rhuph20 to humalog (insulin lispro) for the treatment of type 1 diabetes mellitus (t1dm) in basal-bolus therapy.

criteria for randomization into the study included 1) fasting blood glucose and predinner glucose values in the range of 70 to 140 milligrams per deciliter (mg/dl) approximately 60% of the time for 7 days prior to randomization 2) 90 minute or 2-hour postprandial blood glucose \<220 mg/dl approximately 70% of the time for 7 days prior to randomization and 3) successfully completed 3 days of 10-point glucose monitoring and have at least 4 self-monitored blood glucose values on all non-10-point monitoring days. participants that did not meet 1 or more of these criteria during a 4- to 6-week titration period were not randomized.

Eligibility criteria:
inclusion criteria: * males or females aged ≥18 years * type 1 diabetes mellitus (t1dm) treated with insulin for ≥12 months * body mass index (bmi) 18.0 to 40.0 kilograms per square meter (kg/m\^2). * hemoglobin a1c (hba1c) level 6.7% to 8.2%, inclusive * fasting c-peptide \<0.6 nanograms per milliliter (ng/ml) * willingness to use twice daily (bid) insulin glargine as basal insulin for the duration of the study * willingness to avoid use of an insulin infusion pump or unblinded continuous glucose monitoring (cgm) during the study exclusion criteria: * known or suspected allergy to any component of any of the study drugs * use of pramlintide within 30 days of screening * use of drugs during the study or within 30 days of screening (such as corticosteroids or antimetabolites) that could interfere with the interpretation of study results or are known to cause clinically relevant interference with insulin action, glucose utilization, or recovery from hypoglycemia * recurrent severe hypoglycemia (more than 2 episodes over the last 6 months) or hypoglycemic unawareness, as judged by the investigator

Keywords: type 1 diabetes
use of boric acid in combination with probiotics for the treatment of vaginal infections

Conditions: Candidiasis; Vaginosis, Bacterial

Summary: the purpose of this study is to determine whether a formula of boric acid and probiotics for vaginal application is effective in the treatment of symptomatic episodes of vulvovaginitis in comparison to pharmacological reference controls (depending on the suspected diagnosis).

multicentre, open, prospective, randomized, controlled. women with suspected vaginal infection will be randomized and distributed into two groups (control or boric acid + probiotics). follow-up will last for three months and consists in 3 visits and a telephone interview.

Eligibility criteria:
inclusion criteria: * age over 18 years and agreement to participate by signing the consent form. * women with clinical manifestations of acute infectious vulvovaginitis (burning, pruritus, erythema, oedema, and abnormal vaginal discharge). exclusion criteria: * clinical findings compatible with chlamydia trachomatis, neisseria gonorrhoeae or trichomonas vaginalis infection. * use of anti-fungal, antibiotic or probiotic medication within last 2 weeks prior to the study. * patients receiving other treatment (drug, probiotics or vitamin supplements) that can significantly interfere with study evaluations during the 3 months of follow-up. * pregnant or high risk for pregnancy.
contingency management in the delivery of haart to drug users in chennai, india

Conditions: HIV; Substance Abuse, Intravenous

Summary: drug use (du) is a major risk factor for hiv infection in many regions of the world. however, as highly active antiretroviral therapy (haart) has been rolled out in south and south east asia, less than 2% of individuals initiated on haart were drug users (dus) or former dus, despite the fact that approximately 20% of hiv infections in the region are ascribed to du. india is home to about 2.4 million hiv-infected individuals. though, injection drug users contribute to only about 3% of all hiv infections in india; it is estimated that there are between 168,000 and 1.1 million dus in india with hiv prevalence about 30%. novel approaches are needed to engage disenfranchised populations in hiv care in lower and middle income countries, where the burden of hiv disease is growing. incentive-based strategies (or contingency management) have been shown to be effective in reducing illicit drug use, smoking cessation, and weight loss. short-term pilot studies have also shown that incentive-based strategies can improve electronically-monitored rates of adherence to haart in the us, and a recent study in africa showed that a small incentive approximately doubled the rate that individuals returned to learn the results of their hiv test. however, to date there is no experience with the use of incentive-based interventions to improve engagement into care and risk-reduction among out-of-care hiv-infected dus in developing world settings. the investigators propose to conduct pilot randomized trial comparing a voucher incentive strategy to a control condition to improve engagement in hiv care and hiv treatment outcomes among out-of-care, treatment-eligible, hiv-infected dus in chennai, india. subjects in the incentive arm will be eligible to earn incentive vouchers for 1) initiating haart at a government-sanctioned hiv treatment clinic, 2) adherence to scheduled follow-up visits at the hiv clinic, and 3) achieving suppression of hiv rna. subjects will be enrolled from a mature research venue in chennai, yr gaitonde centre for substance abuse-related research (yrgcsar), which focuses the epidemiology and natural history of hiv in dus. preliminary data from this pilot study will be used to inform the design of a phase-iii study.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * provide written informed consent * provide a history of injection or non-injection drug use in prior 30 days * documented evidence of hiv infection * be art naïve (by self-report) * satisfy indian national guidelines for initiation of haart (any of the following) * absolute cd4+ count \< 200 cells/ µl * aids-defining illness with any cd4+ count * absolute cd4+ count between 200 - 350 cell/ µl with hiv-related symptoms exclusion criteria: * indicates an intention to migrate in the next 12 months * any medical or psychiatric condition that the study physician believes to be a contraindication to study participation. * enrolled in another hiv treatment program

Keywords: complementary therapies drug users
effect of epinephrine on systemic absorption of mepivacaine in uremic patients

Conditions: Renal Insufficiency, Chronic

Summary: the aim of this study is to determine the effect of epinephrine on systemic absorption of local anaesthetic mepivacaine administered for brachial plexus block in uremic patients scheduled for creation or repair of an arteriovenous fistula. furthermore, an impact of epinephrine on the central circulation and peripheral tissue oxygenation will be evaluated.


Eligibility criteria:
inclusion criteria: * patient acceptance of regional anaesthesia exclusion criteria: * peripheral arteriosclerosis * diabetes mellitus * bleeding disorder * infection at the puncture site * allergy to mepivacaine * pregnancy

Keywords: mepivacaine epinephrine brachial plexus block renal insufficiency
hygiene and bucco-dental status of patients with oral streptococcal endocarditis

Conditions: Infective Endocarditis

Summary: infective endocarditis (ie) is a rare (30 cases / million / year in france) and serious disease (20 % of deaths during hospitalization and 40 % after 5 years). the development of an ie results from the meeting between a bacteremia and a pre-existent heart disorder, most of the time valvular, allowing the transplant of the circulating bacteria and their multiplication in the endocardium. recommendations of prophylactic antibiotic treatment have been established since 1954 for some medical, particularly dental procedures, at the origin of bacteremia. but this policy has recently been questioned because its efficacy has not been demonstrated. the purpose of this study is identify the situations with risk, by comparing the oral health status and the hygiene of patients having an ie with oral streptococci to those in patients having an ie with microorganisms not of oral origin.

it is a case-control observational study. the ie cases are recruited in hospitals participating to the french prospective observational "ei2008" cohort. cases are ie with oral streptococci whereas controls are ie with microorganisms not of oral origin.

Eligibility criteria:
inclusion criteria: * major patient * definite ie caused by oral streptococci (case) or by non-oral pathogens (control) exclusion criteria: -
effect of nitrate-rich fruit and vegetable supplement on blood pressure

Conditions: High Blood Pressure; Flow Mediated Dilation

Summary: it is hypothesized that the daily supplementation of a nitrate-rich, two-ounce fruit and vegetable energy supplement (isagenix international llc) by healthy young adults with a would increase circulating nitrates and improve cardiovascular parameters compared to a nitrate-deficient placebo (prune juice).

endothelial cells of the peripheral vasculature are key sources of vasoactive factors regulating healthy blood pressure. one of the primary vasodilatory factors released from these cells is nitric oxide (no). production of no is stimulated both through enzymatic-dependent mechanisms via no synthase, as well as from dietary intake of nitrate-containing foods or supplements that increase no bioavailability. this study examined whether the daily consumption of a nitrate-rich, two-ounce fruit and vegetable energy supplement (isagenix international llc) would increase circulating nitrates and improve cardiovascular parameters compared to a nitrate-deficient placebo (prune juice). healthy male adults aged 18-40y (n=45) were recruited to participate in this longitudinal double-blind, placebo-controlled, randomized clinical trial. subjects maintained their typical diet and physical activity patterns during the study. anthropometric and cardiovascular (blood pressure and flow-mediated dilation (fmd)) parameters, along with plasma nitrates and nitrites were measured at baseline and after one and two weeks of supplementation. subjects also completed questionnaires on sleep quality and mood. it is hypothesized that the nitrate-rich fvs supplement will provide a good source of dietary nitrates and effectively reduced blood pressure in normotensive, healthy young males.

Eligibility criteria:
inclusion criteria: • healthy men aged 18-40y exclusion criteria: * hypo- or hypertension (blood pressure \ 140/90 * cigarette use within past year * food allergies * specific medication use (nitroglycerin, beta-blockers, calcium channel blockers), * unwillingness to drink juice concentrates and follow study restrictions.

Keywords: beetroot juice nitrates and nitrites